MX2021014680A - Derivado de benzotriazol. - Google Patents
Derivado de benzotriazol.Info
- Publication number
- MX2021014680A MX2021014680A MX2021014680A MX2021014680A MX2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- provides
- present
- benzotriazole derivative
- compound
- Prior art date
Links
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101150116862 KEAP1 gene Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102529 | 2019-05-31 | ||
| PCT/JP2020/021426 WO2020241853A1 (ja) | 2019-05-31 | 2020-05-29 | ベンゾトリアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014680A true MX2021014680A (es) | 2022-04-06 |
Family
ID=73553193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014680A MX2021014680A (es) | 2019-05-31 | 2020-05-29 | Derivado de benzotriazol. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559504B2 (https=) |
| EP (1) | EP3978073B1 (https=) |
| JP (1) | JP7524899B2 (https=) |
| KR (1) | KR20220016124A (https=) |
| CN (1) | CN114174289B (https=) |
| AU (1) | AU2020283361B2 (https=) |
| BR (1) | BR112021023927A2 (https=) |
| CA (1) | CA3142295A1 (https=) |
| ES (1) | ES3047102T3 (https=) |
| MX (1) | MX2021014680A (https=) |
| WO (1) | WO2020241853A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065501T2 (hu) | 2018-08-20 | 2024-05-28 | Janssen Pharmaceutica Nv | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok |
| CN113024399B (zh) * | 2021-03-11 | 2022-09-09 | 华东理工大学 | 药物中间体化合物及其制备方法、应用 |
| KR20230110001A (ko) * | 2022-01-14 | 2023-07-21 | 주식회사 대웅제약 | Ssglt 저해제의 합성에 유용한 중간체의 제조 방법 |
| JP7605446B2 (ja) | 2022-04-28 | 2024-12-24 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| US20250296939A1 (en) * | 2022-04-28 | 2025-09-25 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| WO2024262491A1 (ja) * | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
| WO2025192605A1 (ja) * | 2024-03-12 | 2025-09-18 | 株式会社GALTS Pharma | 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102301867B1 (ko) | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| RU2703456C2 (ru) | 2014-07-25 | 2019-10-17 | Тайсо Фармасьютикал Ко., Лтд. | Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом |
| EP3766878B1 (en) | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| SI3782996T1 (sl) | 2015-06-15 | 2024-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulatorji |
| WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| CN108779108A (zh) | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| EP3551621A1 (en) | 2016-12-12 | 2019-10-16 | GlaxoSmithKline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| JP2020502136A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのビスアリールアミド |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのビスアリール複素環 |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| CA3044773A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019116231A1 (en) * | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| US20210177861A1 (en) | 2017-12-11 | 2021-06-17 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| JP2021524469A (ja) | 2018-05-23 | 2021-09-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのインダン |
| HUE065501T2 (hu) | 2018-08-20 | 2024-05-28 | Janssen Pharmaceutica Nv | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok |
| NZ776102A (en) | 2018-12-05 | 2024-12-20 | Scohia Pharma Inc | Macrocyclic compound and use thereof |
| JP7602469B2 (ja) * | 2019-02-15 | 2024-12-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
| CN114080389B (zh) | 2019-07-03 | 2024-08-30 | 千寿制药株式会社 | Nrf2活性化化合物 |
| EP4110776A1 (en) | 2020-02-28 | 2023-01-04 | Les Laboratoires Servier | New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them |
-
2020
- 2020-05-29 MX MX2021014680A patent/MX2021014680A/es unknown
- 2020-05-29 CN CN202080055155.9A patent/CN114174289B/zh active Active
- 2020-05-29 KR KR1020217042003A patent/KR20220016124A/ko active Pending
- 2020-05-29 CA CA3142295A patent/CA3142295A1/en active Pending
- 2020-05-29 WO PCT/JP2020/021426 patent/WO2020241853A1/ja not_active Ceased
- 2020-05-29 BR BR112021023927A patent/BR112021023927A2/pt unknown
- 2020-05-29 ES ES20815167T patent/ES3047102T3/es active Active
- 2020-05-29 US US17/614,941 patent/US12559504B2/en active Active
- 2020-05-29 AU AU2020283361A patent/AU2020283361B2/en active Active
- 2020-05-29 EP EP20815167.0A patent/EP3978073B1/en active Active
- 2020-05-29 JP JP2021522912A patent/JP7524899B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114174289B (zh) | 2025-03-07 |
| CA3142295A1 (en) | 2020-12-03 |
| AU2020283361A1 (en) | 2022-01-20 |
| EP3978073A4 (en) | 2023-07-12 |
| AU2020283361B2 (en) | 2025-11-27 |
| CN114174289A (zh) | 2022-03-11 |
| US12559504B2 (en) | 2026-02-24 |
| JP7524899B2 (ja) | 2024-07-30 |
| EP3978073B1 (en) | 2025-10-15 |
| WO2020241853A1 (ja) | 2020-12-03 |
| US20220259223A1 (en) | 2022-08-18 |
| JPWO2020241853A1 (https=) | 2020-12-03 |
| ES3047102T3 (en) | 2025-12-03 |
| EP3978073C0 (en) | 2025-10-15 |
| EP3978073A1 (en) | 2022-04-06 |
| KR20220016124A (ko) | 2022-02-08 |
| BR112021023927A2 (pt) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014680A (es) | Derivado de benzotriazol. | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| AR112271A1 (es) | Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| MX391414B (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| MX2018006503A (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2022000944A (es) | Combinaciones, mezclas y composiciones fungicidas y usos de las mismas. | |
| CR20160538A (es) | Combinación | |
| MX2018006800A (es) | Composicion farmaceutica. | |
| MX385269B (es) | Compuesto de sulfonamida o sal del mismo. | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| CL2022000725A1 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| BR112018074985A2 (pt) | composições antibacterianas | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |